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Objective: Total joint replacement has been proposed as an endpoint in disease modifying osteoarthritis
drug (DMOAD) randomized clinical trials (RCTs); however, disparities have generated concerns regarding
this outcome. A combined Osteoarthritis Research Society International (OARSI)/Outcome Measures in
Rheumatology (OMERACT) initiative was launched in 2004 to develop a composite index [‘virtual total
joint replacement’ (VJR)] as a surrogate outcome for osteoarthritis (OA) progression in DMOAD RCTs. Our
objective was to evaluate the prevalence of patients fulﬁlling different thresholds of sustained pain,
reduced function, and X-ray change in existing DMOAD RCTs.
Design: Post hoc analysis of summary data from the placebo arm of eight DMOAD RCTs.
Results: Eight OA RCTs representing 1379 patients were included. Pain was assessed by WOMAC and/or
VAS and function by WOMAC and/or Lequesne. Among six knee and two hip studies, 248 (22%) and 132
(51%) patients respectively had X-ray progression [decrease joint space width (JSW) 0.5 mm]. The
prevalence of patients fulﬁlling clinical and radiographic criteria was highest (n ¼ 163, 12%) in the least
stringent scenario (pain þ function 80 at 2 visits); with few patients (n ¼ 129, 2%) in the most
stringent scenario (pain þ function 80 at 4 visits). Using these prevalence data, a sample size of 352e
2144 per group would be needed to demonstrate a 50% difference between groups.
Conclusions: The prevalence of patients with sustained symptomatic OA of at least a moderate degree
with X-ray progression is low. Even using lenient criteria to deﬁne VJR, large patient numbers would be
required to detect differences between groups in DMOAD RCTs. Investigation of the optimal cutoff
threshold and combination of symptoms and radiographic change should be pursued.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The mission of drug development in disease modifying osteo-
arthritis drugs (DMOADs) is to alter the natural history of osteoar-
thritis (OA). This requires carefully designed and meticulously: R.L. Manno, Johns Hopkins
enter Tower, Suite 4100, 5200
0-0722; Fax: 1-410-550-2072.
s Research Society International. Pexecuted randomized clinical trials (RCTs) of potential DMOADs
with clear, accurate, and measurable outcomes that correspond to
OA progression. For most disease processes, the deﬁnitive endpoint
(‘gold standard’) is death or organ failure. In OA, thiswould translate
to ‘joint death’ or ‘joint failure’. However, determining exactlywhen
such a state has been reached is challenging and imprecise. There is,
in fact, no ‘gold standard’ at this time for OA related ‘joint failure’;
nor is there an accepted measurement of OA disease progression
which would classify such a ﬁnal state. Therefore, a surrogate
outcome for OA joint failure, one that represents the naturalublished by Elsevier Ltd. All rights reserved.
Table I
Nine clinical scenarios of sustained symptoms for VJR
Scenario Symptom threshold* Duration of symptomsy
A Pain þ function 80 2 consecutive visits
B Pain þ function 80 3 consecutive visits
C Pain þ function 80 4 consecutive visits
D Pain þ function 100 2 consecutive visits
E Pain þ function 100 3 consecutive visits
F Pain þ function 100 4 consecutive visits
G [pain 50 and function 30] OR
[function 50 and pain 30]
2 consecutive visits
H [pain 50 and function 30] OR
[function 50 and pain 30]
3 consecutive visits
I [pain 50 and function 30] OR
[function 50 and pain 30]
4 consecutive visits
* Each pain and function tool is normalized to 0e100 scale (0 ¼ best,
100 ¼ worst).
y Consecutive visits are 3e6 months apart.
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a DMOAD RCT, a surrogate outcome for ‘OA joint death’ would
represent failure of medical therapy to prevent progression of
disease. Theoretically, in addition to being a clear measurable
endpoint, a surrogate outcome in OA could also allow for increased
frequency of events in DMOAD RCTs therefore decreasing the total
sample size necessary to see a difference between treatment groups.
Total joint replacement (TJR) has been proposed as a primary
outcome in DMOAD RCTs1e3 as this procedure typically improves
pain, function, and the structural joint derangement caused by OA.
TJR is easy to measure and dichotomous. However, overall the
number of OA patients who reach this endpoint is small and
important disparities in TJR by race, gender, socioeconomic status,
access to care, surgeon preference, and health care systems have
generated signiﬁcant concerns that TJR may represent an inaccu-
rate outcome4e8. Further, the decision to recommend TJR by
orthopedic surgeons is complex as recently established in a large
international study that demonstrated signiﬁcant overlap in
symptom severity between those who were and were not recom-
mended for TJR, even after adjusting for radiographic severity9.
In 2004, the international organizations Outcome Measures in
Rheumatology (OMERACT) and Osteoarthritis Research Society
International (OARSI) embarked on a combined initiative to develop
a composite index to be used in lieu of TJR as an endpoint in clinical
trials evaluating potential DMOADs10,11. It was determined that such
a composite index should incorporate key symptomatic (i.e., pain,
functional impairment) and structural variables of OA11. Patients
meeting criteria for this composite index could be considered as
having a ‘virtual joint replacement’ (VJR) with sustained pain,
reduced function, and evidence of X-ray progression. The concep-
tual goal of the VJR endpoint in DMOADRCTs is to eliminatemany of
the biases associated with TJR as a study outcome while still
employing the concept of a dichotomous, OA-speciﬁc outcome.
It is important to note that the intention of these OMERACT/
OARSI VJR criteria is not for use in clinical practice; nor is the
objective of this composite index (VJR) for its use as a threshold at
which to recommend surgery. Rather, this is a construct to be
examined in the context of DMOAD RCTs to determine if a drug is
having an effect on the progression of OA. For example, if the VJR
composite index is used as the primary endpoint in a DMOAD RCT
comparing drug A to drug B for knee OA, the results could be stated
as: “a greater disease-modifying beneﬁt was demonstrated for drug
A compared to drug B among knee OA patients with 30% fewer
patients receiving drug A reaching the VJR endpoint.”
The objective of the current phase of this OARSI/OMERACT
initiativewas to evaluate several different thresholds of symptomatic
severity and structural change to determine the feasibility and
sample size requirement for each scenario if it were to be used as
aVJRoutcome in aDMOADRCT. There are nopublished reports in the
literature about which scenario is optimal. We aimed to achieve this
by establishing the prevalence of patients fulﬁlling different clinical
(pain, functional impairment) and/or X-ray progression scenarios in
a post hoc analysis of the placebo arm of existing DMOAD RCTs.
Methods
Selection of key domains to deﬁne OA progression
In 2004, a steering committee of OARSI/OMERACT members
conducted a review of the literature and selected three domains to
deﬁne OA severity in the context of clinical decision making when
referring a patient for TJR. These three domains are: pain, func-
tional status, and structural damage1. These domains, commonly
captured in all clinical trials, were used to develop potential
composite indices and binary outcomes (VJR) for DMOAD RCTs.Determining thresholds for pain and functional disability
An international prospective observational cross-sectional
study of patients with knee or hip OA was conducted, also under
the auspices of this OARSI/OMERACT initiative, to determine if
cutoff points could be established for pain and functional disability
using TJR as the gold standard9. These data ultimately could not
identify a speciﬁc cut point for pain or functional disability to
discriminate between those who did or did not receive TJR;
although those who did receive TJR were more symptomatic9.
Elaboration of clinical and radiographic criteria to generate VJR
scenarios
The OARSI/OMERACT working group consensus was that all
three domains (pain, functional disability, and structural derange-
ment) should be components of the proposed outcome “VJR”. In
addition to setting thresholds for each domain, it was determined
that sustainability and persistence of symptoms were important
components for VJR as well. Therefore, nine VJR clinical scenarios
with varying thresholds of pain and function were generated by
group consensus (Table I). These scenarios proposed three symp-
tomatic cutoffs: (1) pain þ function 80, (2) pain þ function 100,
(3) [(pain 50 þ function 30) OR (function 50 and pain 30)].
These cutoffs are assuming pain and function measures are
normalized to a scale of 100 (zero being the best and 100 the worst
condition). A composite score of ‘pain and function’ was ascer-
tained by simply adding the two scores: painplus function (each on
a scale of 100 for a maximum potential combined score of 200). The
symptomatic cutoffs for a non-acceptable symptomatic state
(NASS) were combined with three thresholds of symptom
sustainability: (1) NASS during at least two consecutive study visits,
(2) NASS during at least three consecutive study visits, (3) NASS
during at least four consecutive study visits. It should be noted, that
in the deﬁnition proposed by this working group, the consecutive
visits could be at any time during the duration of the study, but
should be of at least 3-month intervals.
Just as it was determined that OA symptoms of pain and func-
tion had to be sustainable and persistent to indicate OA disease
progression, for the domain of structural derangement the OARSI/
OMERACT working group determined that progression of structural
damage (i.e., evidence of signiﬁcant structural change) was
a requisite component for the outcome VJR12. X-ray progression
was deﬁned two ways: decrease in joint space width (JSW)
0.5 mm and decrease beyond the smallest detectable difference
(SDD)13e15. X-ray progression deﬁned by SDD was only utilized in
those studies that reported a SDD.
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of structural damage to generate a binary outcome, ‘VJR’, which
would represent fulﬁllment of symptomatic criteria (one of the
nine scenarios) and evidence of progressive structural damage from
OA (D JSW).
Selection of DMOAD RCTs
Investigators with available databases from recent DMOAD RCTs
of hip or knee OA were invited to participate in these post hoc
analyses. To be included in this study, the DMOAD RCT had to have
a clearly deﬁned placebo group as only placebo arm data was utilized
for analyses in this phase of the VJR initiative to eliminate any
potential treatment-related confounders. Further, the DMOAD RCT
had to have repeat measures of pain and function throughout the
trial (every 3e6 months) and evaluation of radiologic OA parame-
ters at baseline and study end (duration 1 year).
Once selected for these post hoc analyses, investigators from
each included DMOAD RCT were provided with an extensive case
report form (CRF). The investigators from each study had access to
individual patient-level data for the placebo arm of their particular
study. Each investigator then completed analyses of these patient-
level data according to the CRF which required the calculation of
summary statistics [mean  standard deviation (SD)] for baseline,
ﬁnal (i.e., study end), and calculated change during the study for
clinical symptoms (pain, function, pain þ function) and JSW (in
millimeters). From these individual patient-level data, the investi-
gators were also asked to determine howmany individuals met the
nine VJR scenarios and criteria for X-ray progression. For DMOAD
RCTs that did not report a SDD, then only change in JSW was
included. Since the nine clinical scenarios required sustained
symptoms missing data for a speciﬁc visit in a single study was
resolved by averaging the previous available data with the next
available data point.
These analyses (from the CRF) were then forwarded to our
senior biostatistician. The data presented in this paper represent
the combined work from the CRFs by the senior biostatistician. It is
notable, that he did not have access to individual patient-level data
only the summary data from the CRFs. The senior biostatistician of
this OARSI/OMERACT project then completed analyses of the
aggregate summary data obtained from the CRF of each study.
Statistical analyses
Descriptive statistics [mean  SD, median, 95% conﬁdence
interval (CI)] for baseline pain, function, pain þ function, and JSWTable II
Baseline study characteristics of eight randomized controlled trials of disease modifying
Study N* Study duration
(weeks)
# of visits
during
the trialy
Duration
between study
visits (weeks)z
DOXY18 155 120 13 8
ECHODIAH16 136 156 12 13
ERADIAS20 127 156 7 26
GAIT22 50 104 8 13**
KOSTAR19 625 104 4 24
PAVELKA17 54 156 12 12
REGINSTER21 69 156 9 16
STOPP23 163 104 8 12
* Number of participants in the placebo arm with baseline radiographic measures.
y Starting at month 3 after baseline and including the visit at month 3.
z The number of weeks between visits starting at month 3.
** There were two visits from month 3 to month 6, at 8 and then 13 weeks apart.
yy These studies, in addition to deﬁning X-ray progression as change in JSW > 0.5 mmmeasurements were recorded for each DMOAD RCT, and pooled,
weighted means for all baseline measures were generated to
account for the wide variation in sample size.
The total number of patients fulﬁlling criteria (i.e., prevalence)
for radiographic progression (decrease JSW 0.5 mm or decrease
JSW > SDD) and each of the clinical scenarios (Table I; A through I)
was determined. Then the prevalence of patients fulﬁlling criteria
for both radiographic progression and each clinical scenario was
determined.
The discriminant capacity of the clinical scenarios (Table I, AeI)
for X-ray progression (D JSW)was based on the aggregate data from
all DMOAD RCTs. For these analyses, for each study, and for each
clinical scenario two analyses were conducted: (1) radiographic
progression was reported as a continuous variable [D JSW as
outcome, mean (SD)] according to each clinical scenario yes/no
(dichotomous variable) allowing us to calculate an effect size
through standardized mean difference; (2) radiographic progres-
sion was reported as D JSW 0.5 mm (yes/no) according to each
clinical scenario (yes/no) allowing us to calculate an odds ratio.
Then, meta-analysis pooled odds ratios and effect sizes were
generated using meta-analysis software (Revman) with heteroge-
neity assessment and using randomized model effects. Covariates
could not be included in these models as the data utilized were the
aggregate data from each DMOAD RCT CRF (summary data) and not
individual patient-level data.
The sample size necessary for a future RCT to detect a 30% or 50%
difference in proportions between treatment arms was estimated
for each VJR scenario (each clinical scenario plus radiographic
progression). These sample size estimates were calculated using
the prevalence estimates above and based on a ¼ 0.05 and b ¼ 0.2
and did not account for a drop-out rate.
Statistical analyses for the pooled data analyses were performed
using SAS, version 9.1. All reported P-values are two sided with
a ¼ 0.05.Results
DMOAD RCTs
Data from placebo arms of eight RCTs of putative DMOADS for
OA were included in these post hoc analyses: ECHODIAH [Evalu-
ation of the structure-modifying effects of diacerein in hip OA:
ECHODIAH, a 3-year, placebo-controlled trial. Evaluation of the
Chondromodulating Effect of Diacerein in OA of the Hip]16,
PAVELKA [Glucosamine sulfate use and delay of progression of
knee OA: a 3-year, randomized, placebo-controlled, double-blindOA therapies included in these post hoc analyses
OA site Pain tool Function tool X-ray progression
deﬁned by SDDyy
Knee WOMAC, VAS WOMAC 0.50 mm
Hip VAS Lequesne N/A
Hip WOMAC, VAS WOMAC,
Lequesne
N/A
Knee WOMAC WOMAC 0.32 mm
Knee WOMAC WOMAC 0.20 mm
Knee WOMAC WOMAC N/A
Knee WOMAC WOMAC N/A
Knee WOMAC, VAS WOMAC 0.284 mm
, also analyzed their data by change in JSW > SDD.
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results of a randomized, placebo-controlled, double-blind trial]18,
KOSTAR [Risedronate decreases biochemical markers of cartilage
degradation but does not decrease symptoms or slow radio-
graphic progression in patients with medial compartment OA of
the knee: results of the 2-year multinational knee OA structural
arthritis study]19, ERADIAS [Evaluation of the structure-modifying
effect of Avocado-Soybean Unsaponiﬁables (ASU) in Hip OA:
results of the ERADIAS study, a 3-year, prospective, randomized,
double-blind, placebo-controlled trial]20, REGINSTER [Long-term
effects of glucosamine sulfate on OA progression: a randomised,
placebo-controlled clinical trial]21, GAIT [The effect of glucosamine
and/or chondroitin sulfate on the progression of knee OA:
a report from the glucosamine/chondroitin arthritis intervention
trial]22, STOPP [Long-term effects of chondroitins 4 and 6 sulfateTable IIa
Inclusion and exclusion criteria for each study included in these post hoc analyses
Study Age range
(years)
OA inclusion criteria Exclusion crite
DOXY18 45e64 \; BMI*; unilateral
radiographic knee OAy
Posttraumatic
inﬂammatory a
ECHODIAH16 N/A Daily hip pain 1 month;
Lequesne 3; JSW 1e3 mm
Secondary hip
femoral head m
ERADIAS20 45 Primary hip OA; JSW 1e4 mm;
Lequesne 30
Not available
GAIT22 40 Knee pain 6 months;
Kellgran/Lawrence
grade 2e3 knee OA
History of trau
JSW <2 mm; a
<6 months; pr
lateral compar
KOSTAR19 40e80 Knee pain >1 monthyy;
JSW 2e4 mm þ 1 osteophyte
in the medial tibiofemoral
compartmentzz
Inﬂammatory a
>40 kg/m2; ca
10 years
PAVELKA17 45e70 Knee OA of the medial
femorotibial compartmentyyy;
Lequesne 4
Lequesne >12;
arthritis; traum
> 27 kg/m2, di
REGINSTER21 >50 Knee OA of the medial
femorotibial compartmentyyy
Inﬂammatory a
BMI > 30 kg/m
STOPP23 45e80 Knee OA of the medial
femorotibial compartmentyyy;
JSW  1 mm; VAS 30 for
>3 months
Kellgran/Lawre
isolated lateral
patellofemoral
trauma; second
hip surgery
* Upper tertile of age- and race-adjusted norms for body mass index (BMI) in women
y According to American College of Rheumatology (ACR) criteria with Kellgran/Lawr
contralateral knee.
z Except during the ﬁnal 24 h washout period.
** 3e7 days washout period before study visits; no intraarticular or systemic corticost
yy Knee pain due to OA on most days during at least 1 month in a 3-month period prio
<30 min, or knee crepitus according to ACR criteria for knee OA.
zz Plus a medial compartment that was narrower than the lateral.
*** Acetaminophen/paracetamol and diclofenac were to be used as the only pain medic
pain medications were discontinued on day -2 & day -1 prior to these visits & on the vi
yyy Based on ACR criteria for OA.
zzz Acetaminophen only.
**** Appropriate washout periods before symptom assessment: 24 h for acetaminophenon knee OA: the study on OA progression prevention, a 2-year,
randomized, double-blind, placebo-controlled trial]23.
The characteristics of these eight DMOAD RCTs are described in
Table II and Table IIa. There were two studies of hip OA (ECHODIAH,
ERADIAS). The remaining six RCTs were of knee OA. Pain was
assessed by Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) and/or Visual Analog Scale (VAS)24, and
function was assessed by WOMAC and/or Lequesne25 in all studies.
Three studies had a minimum level of pain at baseline (on
a normalized scale 0e100) required for entry into the study:
ERADIAS (Lequesne 30), GAIT (WOMAC >25), STOPP (WOMAC/
VAS >30). None of the studies had a minimum level of baseline
function required for entry. Of note, both PAVELKA and REGINSTER
required a minimum severity at enrollment of four points on the
Lequesne Algofunctional Index. All eight studies included JSWria by arthritis Exclusion criteria by treatment Pain medication
permitted?
arthritis;
rthritis
Tetracycline allergy; intraarticular
hyaluronan <6 months; intraarticular
corticosteroid <3 months
Yesz
OA; medial
igration
Intraarticular injection or surgery
<3 months; contralateral THR
<6 months
Yes**
Not available Not available
ma;
rthroscopy
edominate
tment OA
Oral/IM corticosteroids <1 month;
intraarticular steroids to study joint
<3 months; intraarticular steroids to
any other joint <1 month; hyaluronic
acid or congeners into the study joint
<12 months; topical analgesics to the
study joint or any oral analgesics
<2 weeks or during the study;
implementation of any other medical
therapy for arthritis <1 month;
glucosamine <3 months or
chondroitin <6 months; initiation of
physical therapy or muscle condition
program <2 months; use of
anticoagulants
Yeszzz
rthritis; BMI
ncer within
Tetracycline use within 6 months;
intraarticular corticosteroids or
hyaluronan <3 months; calcitonin or
ﬂuoride<6 months; bisphosphonates
<12 months or for >60 days ever
Yes***
inﬂammatory
a; BMI
abetes
Systemic or intraarticular
corticosteroids <3 months
Yeszzz
rthritis; trauma;
2
Systemic or intraarticular
corticosteroids <3 months
Yes
nce grade 4;
tibiofemoral or
OA; surgery;
ary OA; hip OA;
Intraarticular injection <3 months;
treatment with symptomatic
slow-acting or disease modifying
OA drugs <3 months;
corticosteroids <1 month
Yes****
.
ence (K/L) grade 2 or 3 changes in the index knee and grade 0 or 1 changes in the
eroids were allowed.
r to screening plus at least 1 of the following: age >50 years, morning knee stiffness
ations from day -5 to day -3 preceding the baseline, 6-, 12-, 18-, 24-month visits; all
sit day.
and 5 days for NSAIDs; i.e., at least ﬁve half-lives of the selected medication.
Table III
Summary baseline pain, function, and JSW measures of the eight randomized controlled trials of disease modifying OA therapies included in these post hoc analyses
Study Mean
pain*
 SD
Median pain*
(95% CI)
Mean
function*
 SD
Median function*
(95% CI)
Mean JSW
(mm)y  SD
Median JSW (mm)y
(95% CI)
DOXY18 27  20 25 (24, 30) 28  18 28 (25, 31) 3.69  1.14 3.86 (3.51, 3.87)
ECHODIAH16 42  18 43 (39, 45) 30  9 29 (28, 32) 2.39  0.77 2.30 (2.26, 2.52)
ERADIAS20 36  24 34 (0, 84) 29  9 29 (11, 48) 2.85  0.90 2.80 (1.09, 4.61)
GAIT22 46  14 45 (42, 50) 47  18 44 (42, 52) 3.94  1.01 3.98 (3.66, 4.23)
KOSTAR19 40  22 39 (38, 42) 44  23 44 (42, 46) 2.96  0.59 2.99 (2.92, 3.01)
PAVELKA17 31  16 30 (27, 36) 30  16 29 (26, 34) 3.80  1.57 3.75 (3.37, 4.23)
REGINSTER21 33  21 31 (28, 38) 38  22 34 (32, 43) 4.05  1.25 4.10 (3.76, 4.35)
STOPP23 38  20 36 (35, 42) 38  21 35 (35, 41) 3.69  1.20 3.75 (3.51, 3.88)
* At baseline entry into the individual study for all participants; normalized to scale of 0e100; 95% CI is for the mean.
y JSW in millimeters at baseline entry into the individual study for all participants.
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graphic progression was evaluated in these post hoc analyses using
the cutoff of SDD (range 0.20e0.50mm) in four of the DMOADRCTs.
The eight OA RCTs were between 1 and 3 years duration and
represented 1379 [note: only 1354 with pain/function measures]
patientswithOA. The baseline pain, function, andX-ray data for each
study are summarized in Table III. The weighted baseline means
among all eight studies were: JSW 3.18mm (range: 2.39e4.05), pain
score 37.8 (range: 31.0e45.8), function score 38.0 (range: 29.5e47.1),
and pain þ function 76.8. The number of patients that met symp-
tomatic criteria at baseline is summarized in Table IIIa.
Among six knee and two hip studies, 248 (22%) and 132 (51%)
patients, respectively, had X-ray progression as deﬁned by change
in JSW greater than or equal to 0.5 mm by the study’s end. Among
the four studies (DOXY, GAIT, KOSTAR, STOPP) that included
radiographic progression measurements by decrease greater than
SDD (of note, all were of knee OA), 366 patients (37%) met criteria
for X-ray progression by decrease in JSW greater than SDD.
With all of the studies combined, the prevalence of patients
fulﬁlling criteria for each of the nine clinical scenarios [Fig. 1(A),
Table I] was highest (n ¼ 486, 36%) in the least stringent scenario
(Scenario A: pain þ function 80 at 2 visits), and the fewest
patients (n¼ 101, 7%) fulﬁlled criteria in themost stringent scenario
(Scenario F: pain þ function 80 at 4 visits). This trend was
maintainedwhen the studieswere stratiﬁedbyOA site (hip vs knee).
When radiographic progression (deﬁned as change in JSW
0.5 mm) was added to the clinical scenarios, the prevalence of
patients fulﬁlling a complete VJR scenario (both symptoms and
radiographic progression) ranged from 2.2% to 12.1% [Fig. 1(B)].
Among the four studies analyzed also by SDD, the prevalence of
patients fulﬁlling a complete VJR scenario when deﬁning radio-
graphic progression as change in JSW  SDD was 3.4e16.7%.Table IIIa
Number of patients from each DMOAD RCT who met symptomatic criteria for Scenarios
Pain þ function 80 at baseline
All patients Patients with Rx progress
(change >0.5 mm)
N (%)y N
ECHODIAH16 52 (39%) 30
ERADIAS20 46 (36%) 24
PAVELKA17 14 (26%) 3
REGINSTER21 26 (38%) 12
DOXY18 37 (24%) 16
GAIT22 30 (60%) 4
KOSTAR19 316 (53%) 55
STOPP23 68 (42%) 19
* Number of patients from each DMOAD RCT who met symptomatic criteria at baselin
study.
y Percentage of patients from corresponding DMOAD RCT who met symptomatic critAlthough individual studies demonstrated associations between
a particular clinical scenario (AeI) and radiographic progression
(D JSW >0.5 mm), in the pooled meta-analyses of all eight DMOAD
RCTs (pooled odds ratio or effect size) there were no statistically
signiﬁcant relationships (Table IV). There was considerable
heterogeneity with I2 results ranging from 17.8% to 62.8% (OR) and
48.5% to 69.4% (ES) across the scenarios.
The sample size required per study arm to demonstrate a 30% or
50% difference between treatment and placebo groups ranged from
352 to 6692 patients (per arm) (Table V).Discussion
In this post hoc analysis from the placebo group of eight large
DMOAD RCTs with plain radiographic endpoints representing over
1300 patients with OA we found that the prevalence of patients
with sustained symptomatic OA of at least moderate degree with
evidence of radiographic progression is overall quite low. The
scenario with the most lenient criteria to deﬁne VJR (Scenario A:
pain þ function 80 for 2 consecutive visits) had the highest
prevalence (12.14%) even when combined with radiographic
progression. To use this VJR criteria (Scenario A plus radiographic
progression) as the primary outcome in a DMOAD RCT, 352 patients
per study arm would be required to detect a 50% difference
between groups.
These data and the overall impact of this OARSI/OMERACT
initiative are best interpreted in the context of the OMERACT
ﬁlter26. The OMERACT ﬁlter is composed of three key components:
truth, discrimination, and feasibility. Each component criterion
represents a question to be answered of an outcome measure in its
intended settings.AeF at baseline
Pain þ function 100 at baseline
ion* All patients Patients with Rx progression*
(change >0.5 mm)
N (%)y N
16 (12%) 7
18 (14%) 9
5 (9%) 1
16 (23%) 7
18 (12%) 10
19 (38%) 2
229 (38%) 42
41 (25%) 9
e (either pain þ function 80 or 100) and radiographic criteria by the end of the
eria at baseline among those with complete pain and function data at baseline.
Fig. 1. PANEL (A): Prevalence of participants (placebo arm of all eight RCT DMOAD studies) meeting criteria for each clinical scenario (AeI) only (not radiographic progression) among
all eight RCTs (n ¼ 1343). PANEL (B): Prevalence of participants (placebo arm of all eight RCT DMOAD studies) meeting criteria for radiographic progression (D JSW 0.5 mm) and
each clinical scenario (AeI) among all eight RCTs (n ¼ 1343).
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The objective of the VJR criteria is to be a meaningful, attainable
outcome in DMOAD RCTs that represents progression of OA (i.e.,
a successful DMOAD would have fewer patients reaching such anoutcome). Cartilage degradation and structural derangement are
inherent pathological processes seen radiographically inOA.However,
providers agree that radiographic features of OA alone are not sufﬁ-
cient to necessitate therapyand symptomsand functional impairment
are equally important aspects of thedisease.Hence, agreement among
Table IV
Discriminant capacity of clinical scenarios on radiographic progression among eight
randomized controlled trials of disease modifying OA therapies included in these
post hoc analyses
Clinical scenario ES* (95% CI) ORy (95% CI)
A 0.19 (0.37, 0.00) 1.40 (0.94, 2.09)
B 0.11 (0.37, 0.14) 1.29 (0.75, 2.22)
C 0.13 (0.43, 0.17) 1.36 (0.78, 2.35)
D 0.31 (0.64, 0.03) 1.35 (0.81, 2.26)
E 0.14 (0.48, 0.21) 1.21 (0.76, 1.91)
F 0.09 (0.44, 0.26) 0.97 (0.54, 1.74)
G 0.18 (0.39, 0.03) 1.30 (0.78, 2.17)
H 0.11 (0.37, 0.14) 1.21 (0.78, 1.86)
I 0.07 (0.37, 0.22) 1.19 (0.66, 2.13)
* Effect size of clinical scenario on radiographic progression (outcome) as
measured by change in JSW as a continuous variable.
y Pooled odds ratio of clinical scenario on radiographic progression (outcome) as
measured by change in JSW as a dichotomous variable (0.5 mm).
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DMOAD research and RCTs, regarding the use of both sustained
symptoms and radiographic progression to fulﬁll VJR criteria
demonstrates the face validity of the VJR as an outcome measure.
The application of the VJR criteria to data collected from eight
DMOADRCTs supports the content validity of thismeasure. However,
there is no ‘gold standard’ for disease progression in the natural
history of OA. Theoretically, this would be ‘joint death’ or ‘complete
joint failure’ which is also difﬁcult to deﬁne as evidenced by the
variability in actual TJR rates9 and small number of patients reaching
this endpoint in DMOAD RCTs. As there is no ‘gold standard’ for
identifying signiﬁcant progression in the natural course of OA, and
VJR criteria could not be tested against such, we are unable to
comment on criterion and construct validity at this time. However, it
will be important for future investigations by this OARSIeOMERACT
initiative to test the VJR scenarios in the context of a large, prospec-
tive longitudinal cohort, such as the OA Initiative (OAI), to establish
such validity. The OAI consortium could also provide valuable data
regarding the prevalence and incidence of VJR scenarios compared to
TJR. This is an important concept that we could not address in these
post hoc analyses becausewe did not consistently have TJR data from
the placebo arm of these DMOAD RCTs.Discrimination
We were not able to demonstrate discriminant capacity as; once
again, there is no gold standard against which tomeasure. Wewere
also not able to determine the measure’s sensitivity to change as
this would require multiple measures of a population over time.
None of the clinical scenarios (AeF) were able to discriminate
between individuals with and without radiographic progression.Table V
Sample size calculations (number of patients required per study arm) based on
prevalence among all eight DMOAD RCTs of each clinical scenario and radiographic
progression (D JSW 0.5 mm) to detect a 30% or 50% difference in proportions
between groups based on a ¼ 0.05 and b ¼ 0.2
Clinical scenario D 30% D 50%
A 1096 352
B 1748 561
C 2632 843
D 1991 637
E 3675 1172
F 6692 2144
G 1472 473
H 2474 790
I 3880 1237Feasibility
The VJR is easy to perform and requires only self-administered
pain and function measures coupled with plain radiography.
These measures are routinely obtained in DMOAD RCTs. However,
we found that using these criteria as the primary outcome in
a DMOAD RCT, 352e1096 individuals per study arm (based on the
prevalence of VJR scenario A with radiographic progression) would
be required to detect at least a 30% improvement over placebo.
Although it is feasible to recruit >500 patients for a DMOAD study
as demonstrated by KOSTAR, one of the largest DMOAD RCTs
included in these analyses with over 500 patients per arm, this will
contribute considerable cost and time to the investigation. Further,
a 50% difference from placebo, which allows for the ‘smallest’
sample size of 352 subjects per arm (VJR scenario A), may represent
a high hurdle for a DMOAD. DOXY reported a 33% improvement
over placebo in loss of JSW at 30 months, and ECHODIAH reported
a 32% improvement over placebo in median annual joint space
narrowing rate after 3 years. Changing the assumption to detect
a 30% improvement over placebo with VJR Scenario A signiﬁcantly
increases the sample size from a somewhat manageable 352
subjects per arm to a much larger study of 1096 per arm. It is also
important to note that these sample size calculations do not
account for drop-out rates which are usually >20% in long-term
DMOAD RCTs. For these reasons, the VJR is a feasible measure
given its ease of administration, but due to the overall low preva-
lence and incidence of even the least stringent VJR scenario, large
sample sizes will be required making implementation costly and
time-consuming.
A primary strength of this study is the large number of inter-
national OA patients with serial pain, function, and radiographic
measures. This is the ﬁrst analysis of pooled data from across
existing DMOAD clinical trials. It reﬂects the involvement of an
international working group and the input of various investigators
and organizations to address a critical question to facilitate DMOAD
development.
The primary limitation of this study is that it is a post hoc
analysis of summary data. For this reason we were unable to
perform analyses related to individual patient-level data or control
for confounders such as rescue medication use. Further, these
studies differed signiﬁcantly in terms of follow up time, frequency
of assessment (number of visits, time between visits), protocol for
acquisition of radiographic data, and inclusion criteria. There was
a low level of pain among all of the studies at entry. Due to the slow
progression and episodic nature of symptom exacerbations in OA,
these patients with low levels of symptoms would be less likely to
have sustained severe symptoms over time compared to patients
with high levels of baseline symptoms. There is inherent difﬁculty
however in enrolling patients with high levels of pain in a long-
termDMOAD study because if pain is not adequately addressed, it is
expected that a high number of patients may not remain in the
study over time. There were several differences between the hip
and knee OA DMOAD RCTs, most notably, there was a higher inci-
dence of radiographic progression among the two hip OA studies
(n ¼ 132, 50.6%) compared to the six knee OA studies (n ¼ 380,
27.6%). There was a signiﬁcant amount of variability in the preva-
lence of radiographic progression in the knee OA studies as well
(range: 15e45%). This heterogeneity may have contributed signif-
icantly to the pooled results, and potential VJR scenarios may need
to be identiﬁed with studies limited to a single OA site. Finally,
these data are based on X-ray radiography with the method of
acquisition and analysis of images variable from study to study.
Imaging with magnetic resonance imaging (MRI) may be a more
sensitive measure of OA progression; however these methods are
not yet standardized.
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considered with additional criteria. We only assessed JSW by
change. By incorporating an absolute JSW cut-off wemay be able to
capture a larger group of patients who meet VJR criteria. It is likely
that the inclusion of additional criteria would further increase the
sample size requirements for studies. As there may be a group
whose symptoms correlate more closely with change in JSW,
further subgroup analyses, based on baseline JSW, may also be
explored. This may be best addressed in an epidemiologic setting
because many of the DMOAD RCTs had entry criteria which
included a minimum JSW. Future studies should also consider the
evaluation of known OA risk factors (i.e., age, history of trauma)
with the VJR scenarios, and the sustainability of the VJR scenarios
over time (i.e., the duration with which patients continue to meet
VJR criteria).
The advancement of drug development for disease modifying
medications for OA is of critical importance and requires robust
studies with feasible sample sizes, reasonable duration of follow up
time, and reliable, valid outcome measures. Ongoing investigation
of the optimal cutoff threshold and combination of symptoms and
radiographic change should be pursued.
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